105
Participants
Start Date
December 21, 2017
Primary Completion Date
November 21, 2019
Study Completion Date
February 24, 2020
Placebo
Placebo (Matched with ISIS 703802)
ISIS 703802 40 mg
ISIS 703802 40 mg, administered via SC injection, once every 4 weeks for 6 doses.
ISIS 703802 80 mg
ISIS 703802 80 mg, administered via SC injection, once every 4 weeks for 6 doses.
ISIS 703802 20 mg
ISIS 703802 20 mg, administered via SC injection, once every week for 26 doses.
Clinical Site, High Point
Clinical Site, Greensboro
Clinical Site, Charleston
Clinical Site, Atlanta
Clinical Site, Miami
Clinical Site, Jupiter
Clinical Site, Boca Raton
Clinical Site, Port Saint Lucie
Clinical Site, Jensen Beach
Clinical Site, Louisville
Clinical Site, Cincinnati
Clinical Site, Cincinnati
Clinical Site, Indianapolis
Clinical Site, Edina
Clinical Site, Chicago
Clinical Site, Carrollton
Clinical Site, Dallas
Clinical Site, Hurst
Clinical Site, Houston
Clinical Site, San Antonio
Clinical Site, San Antonio
Clinical Site, Austin
Clinical Site, Layton
Clinical Site, Phoenix
Clinical Site, Phoenix
Clinical Site, Phoenix
Clinical Site, Mesa
Clinical Site, Mesa
Clinical Sites, Chandler
Clinical Site, Fountain Hills
Clinical Site, Glendale
Clinical Site, Los Angeles
Clinical Site, Huntington Park
Clinical Site, Panorama City
Clinical Site, Montclair
Clinical Site, Poway
Clinical Site, Bridgeton
Clinical Site, Princeton
Clinical Site, Hamilton
Clinical Site, Toronto
Clinical Site, Chicoutimi
Clinical Site, Montreal
Lead Sponsor
Collaborators (1)
Ionis Pharmaceuticals, Inc.
INDUSTRY
Akcea Therapeutics
INDUSTRY